Introduction: Gemcitabine is a chemotherapeutic agent used to treat several solid organ malignancies. The most common cutaneous toxicities are a mild erythematous rash and pruritus, which are often attributed to infectious etiologies. However, certain clinical characteristics may favor a drug-related reaction. Clinicians should recognize these phenomena to avoid potentially unnecessary antibiotic treatment or withdrawal of chemotherapeutic agents.
Objective: We aim to report a case of gemcitabine-related acute lipodermatosclerosis-like eruption, add to the evolving classification of this condition, and highlight developing literature on gemcitabine that may explain this toxicity.
Case: Dermatology was consulted for presumed cellulitis in a 62-year-old female with pancreatic carcinoma. The patient presented to the emergency department five days after her first dose of gemcitabine with erythema in both lower extremities. A diagnosis of gemcitabine-related acute lipodermatosclerosis was made and the patient was started on topical triamcinolone.
Conclusion: It is important to recognize gemcitabine-related acute lipodermatosclerosis in order to avoid unnecessary antibiotic use and disruptions in chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1078155218788709 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gemcitabine-Related Acute Coronary Syndrome.
J Med Cases
January 2020
Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
A strong association of gemcitabine to acute coronary syndrome (ACS) is not currently established in the literature. In this series, we highlight that both patients with gemcitabine-related ACS were more than 50 years old, had underlying coronary artery disease and suffered from metastatic cancer. However, further prospective studies are required to validate the significance of these observations.
View Article and Find Full Text PDFPectoralis major radiation recall.
J Med Radiat Sci
March 2019
Department of Medicine, Royal Darwin Hospital, Tiwi, Northern Territory, Australia.
Radiation recall is an uncommon phenomenon describing an acute localised inflammatory toxicity affecting tissue previously exposed to radiotherapy. It is precipitated by administration of certain medications, including chemotherapy. We describe a case involving a 50-year-old Aboriginal male smoker from a remote community in Northern Australia who underwent treatment for stage IV non-small cell lung cancer with localised radiotherapy to the primary right upper lung lobe tumour.
View Article and Find Full Text PDFA case of gemcitabine-related acute lipodermatosclerosis.
J Oncol Pharm Pract
July 2019
2 Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, USA.
Introduction: Gemcitabine is a chemotherapeutic agent used to treat several solid organ malignancies. The most common cutaneous toxicities are a mild erythematous rash and pruritus, which are often attributed to infectious etiologies. However, certain clinical characteristics may favor a drug-related reaction.
View Article and Find Full Text PDF[Two Case Reports of Chemotherapy-Induced Radiation Myositis].
Gan To Kagaku Ryoho
June 2018
Dept. of Radiation Oncology, Hiroshima Prefectural Hospital.
Radiation recall is regarded as an acute inflammatory reaction that is triggered by cytotoxic agents within a previously irradiated area, and the most common site is the skin. Gemcitabine-related radiation recall is rare, and most reported cases involving gemcitabine occur in the muscle, unlike those of other chemotherapeutic agents. Here, we report 2 cases of chemotherapy- induced radiation myositis.
View Article and Find Full Text PDFExacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion.
Int Cancer Conf J
January 2017
Tokyo-Edogawa Cancer Center, Edogawa Hospital, 2-24-18 Higashikoiwa, Edogawa-ku, Tokyo, 133-0052 Japan.
Late-onset gemcitabine pulmonary toxicity is rare and association between pulmonary toxicity and radiotherapy to the extrapulmonary sites is controversial. Here, we report a case of acute exacerbated fatal interstitial pneumonia during radiotherapy to the extrapulmonary site. A 73-year-old woman with pelvic lymph node metastases from urothelial carcinoma underwent palliative radiotherapy after failure of gemcitabine-containing and gemcitabine-non-containing chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!